A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24 Week Study Followed by Long-Term Treatment for Evaluation of Efficacy and Safety of Baricitinib in Patients with Active Psoriatic Arthritis

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24 Week Study Followed by Long-Term Treatment for Evaluation of Efficacy and Safety of Baricitinib in Patients with Active Psoriatic Arthritis

Planning
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Baricitinib (Primary)
  • Indications Psoriatic arthritis
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 01 Aug 2017 According to an Incyte Corporation media release, Lilly no longer plans to initiate a Phase III program to evaluate the safety and efficacy of baricitinib in patients with PsA during 2017.
    • 17 Jan 2017 New trial record
    • 13 Jan 2017 According to an Eli Lilly media release, this study is expected to be initiated in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top